Skip to main content
SpringerLink
Log in

Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: Effect on clinical, biochemical and neurophysiological parameters

  • Neuropediatrics
  • Original Paper
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

We have investigated the effect of glyceroltrioleate/glyceroltrierucate (GTO/GTE) therapy on X-chromosomal adrenoleukodystrophy in 16 patients with adrenoleukodystrophy (n=6), adrenomyeloneuropathy (n=3), Addison disease without neurological involvement (n=2), and neurologically and endocrinologically asymptomatic patients (n=5). Therapy was carried out for 19.4±10 months. All patients showed a normalization of C 26:0 plasma fatty acid concentrations. None of the seven neurologically asymptomatic patients developed neurological symptoms. Somatosensory evoked potentials of the tibialis nerve was the most sensitive electrophysiological parameter, showing a slight improvement in neurologically asymptomatic patients during therapy. In none of the patients with normal cranial MRI at start of therapy (n=6) has MRI deterioration been observed whilst on therapy. Follow up of the neurologically asymptomatic children supports the hypothesis that GTO/GTE therapy might prevent the development of neurological symptoms. Six of the nine neurologically symptomatic patients deteriorated to varying degrees whilst on therapy. MRI alterations have worsened in all patients with clinical deterioration.

Conclusion

GTO/GTE treatment should be initiated in all neurological asymptomatic boys before first neurological symptoms develop. To discover these patients very long-chain fatty acid determination should be performed in all family members at risk when adrenoleukodystrophy or adrenomyeloneuropathy is diagnosed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ADD :

Addison disease

AEP :

auditory evoked potentials

ALD :

adrenoleukodystrophy

AMN :

adrenomyeloneuropathy

ASY :

asymptomatic

GTO :

glyceroltrioleate

GTE :

glyceroltrierucate

NCV :

nerve conduction velocity

SSEP :

somatosensory evoked potentials

VEP :

visual evoked potentials

VLCFA :

very long-chain fatty acids

References

  1. Aubourg P, Blancne S, Jambaque I, Rocchiccioli F, Kalifa G, Naud-Saudreau C, Rolland MO, Debre M, Chaussain JL, Griscelli C, Fischer A, Bougneres P-F (1990) Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med 322: 1860–1866

    PubMed  Google Scholar 

  2. Aubourg P, Adamsbaum C, Lavallard-Rousseau M-C, Rocchiccioli F, Cartier F Jambaque I, Jakobezak C, Lemaitre A, Boureau F, Wolf C, Bougneres P-F (1993) A two-year trial of oleic acid and erucic acids (“Lorenzo's oil”) as treatment for adrenomyleneuropathy. N Engl J Med 329:745–752

    Article  PubMed  Google Scholar 

  3. Boles DJ, Craft DA, Padgett DA, Loria RM, Rizzo WB (1991) Clinical variation in X-linked adrenoleukodystrophy: fatty acid and lipid metabolism in cultured fibroblasts. Biochem Med Metab Biol 45:74–91

    Article  PubMed  Google Scholar 

  4. Brown FR, Van-Duyn MA, Moser AB, Schulman JD, Rizzo WB, Snyder RD, Murphy JV, Kamoshita S, Migeon CJ, Moser HW (1982) Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J 151: 164–172

    PubMed  Google Scholar 

  5. Brown FR, Chen WW, Kirschner DA, Frayer KL, Powers JM, Moser AB, Moser HW (1983) Myeline membrane from adrenoleukodystrophy brain white matter-biochemical properties. J Neurochem 41:341–348

    PubMed  Google Scholar 

  6. Hunneman DH, Hanefeld F (1987) Diagnose von peroxisomalen Erkrankungen-Erfahrungen mit einer empfindlichen massenfragmentographischen Bestimmung der sehr langkettigen Fettsäuren und der Phytansäure im Plasma. Monatsschr Kinderheilkd 136: 529

    Google Scholar 

  7. Kaplan PW, Tusa RJ, Shankroff J, Heller J, Moser HW (1993) Visual evoked potentials in adrenoleukodystrophy: a trial with glycerol trioleate and Lorenzo Oil. Ann Neurol 34: 169–174

    Article  PubMed  Google Scholar 

  8. Lazo O, Contreras M, Hashmi M, Stanley W, Irazu C, Singh I (1988) Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci USA 85:7647–7651

    PubMed  Google Scholar 

  9. Maeda K, Suzuki Y, Yajima S, Asano J, Yamaguchi S, Matsumoto N, Borel J, Moser HW, Orri T (1992) Improvement of clinical and MRI findings in a boy with adrenoleukodystrophy by dietary erucic acid therapy. Brain Dev 14:409–412

    PubMed  Google Scholar 

  10. Moser AB, Borel J, Odone A, Naidu S, Cornblath D, Sanders DB, Moser HW (1987) A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol 21:240–249

    Article  PubMed  Google Scholar 

  11. Moser HW (1993) Lorenzo's oil. Lancet 341:544

    Article  PubMed  Google Scholar 

  12. Moser HW, Moser AB, Frayer KK, Chen W, Schulman JD, Neill B, Kishimoto Y (1981) Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 31:1241–1249

    PubMed  Google Scholar 

  13. Moser HW, Aubourg P, Cornblath D, Borel J, Wu Y-W, Bergin N, Naidu S, Moser AB (1991) The therapy of X-linked adrenoleukodystrophy. In: Desnick RJ (ed) Treatment of genetic diseases. Churchill Livingstone, New York, pp 111–129

    Google Scholar 

  14. Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, Stine OC, Merette C, Ott J, Krivit W, Shapiro E (1992) Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherited Metab Dis 15:645–664

    Article  PubMed  Google Scholar 

  15. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, Poustka AM, Mandel JL, Aubourg P (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361: 726–730

    PubMed  Google Scholar 

  16. Powers JM, Liu Y, Moser AB, Moser HW (1992) The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 51:630–643

    PubMed  Google Scholar 

  17. Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J (1986) Adrenoleukodystrophy: oleic acid lower fibroblast saturated C22–26 fatty acids. Neurology 36:357–361

    PubMed  Google Scholar 

  18. Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS, Avigan J, Proud VK (1987) Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels. Ann Neurol 21: 232–239

    Article  PubMed  Google Scholar 

  19. Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME, Jennings SS, Davis S, Jaitly R, Sgro JA (1989) Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39:1415–1422

    PubMed  Google Scholar 

  20. Stöckler S, Molzer B, Plecko B, Zenz W, Muntean W, Söling U, Hunneman DH, Korenke GC, Hanefeld F (1993) Giant platelets in erucic acid therapy for adrenoleukodystrophy. Lancet 341: 1414–1415

    Article  Google Scholar 

  21. Wanders RJ, Roermund CW van, Wijland MJ van, Schutgens RB, Schram AW, Tager JM, Bosch H van den, Schalkwijk C (1988) X-linked adrenoleukodystrophy: identification of the primary defect at the level of a deficient peroxisomal very long chain fatty acyl-CoA synthetase using a newly developed method for the isolation of peroxisomes from skin fibroblasts. J Inherited Metab Dis 11: 173–177

    Article  PubMed  Google Scholar 

  22. Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M (1991) Experience on therapy of adrenoleukodystrophy and adrenomyleoneuropathy. Dev Neurosci 13:274–279

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics and Neuropaediatrics, University of Göttingen, Robert-Koch-Allee 40, D-37075, Göttingen, Germany

    G. C. Korenke, D. H. Hunneman, J. Konler, S. Stöckler, K. Landmark & F. Hanefeld

Authors
  1. G. C. Korenke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. H. Hunneman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Konler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Stöckler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Landmark
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Hanefeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korenke, G.C., Hunneman, D.H., Konler, J. et al. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: Effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr 154, 64–70 (1995). https://doi.org/10.1007/BF01972976

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01972976

Key words

Search

Navigation